Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a report released on Monday.

Separately, HC Wainwright reissued a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research report on Wednesday, October 23rd.

Akebia Therapeutics Stock Performance

Shares of NASDAQ:AKBA traded down $0.10 during midday trading on Monday, reaching $1.85. The company's stock had a trading volume of 2,388,439 shares, compared to its average volume of 2,994,756. Akebia Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $2.48. The firm has a 50 day moving average price of $1.87 and a two-hundred day moving average price of $1.49. The firm has a market capitalization of $403.63 million, a price-to-earnings ratio of -8.04 and a beta of 0.70.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The firm had revenue of $37.43 million for the quarter, compared to analysts' expectations of $45.66 million. During the same quarter in the prior year, the company earned ($0.08) EPS. As a group, research analysts anticipate that Akebia Therapeutics will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of Akebia Therapeutics by 10.9% in the third quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 9,662 shares during the period. Franklin Resources Inc. bought a new position in Akebia Therapeutics in the 3rd quarter worth about $221,000. Barclays PLC raised its holdings in shares of Akebia Therapeutics by 276.1% in the 3rd quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 200,482 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Akebia Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 4,754,464 shares of the biopharmaceutical company's stock valued at $6,277,000 after acquiring an additional 218,172 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Akebia Therapeutics during the third quarter worth about $58,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.